Vertex’s 2016 outlook falls short amid mixed results from high-profile CF meds

Carly Helfand SAN FRANCISCO–Cystic fibrosis specialist Vertex announced 2015 Kalydeco sales that topped analyst expectations, in advance of a presentation at the ...

Fujifilm’s Toyama unit set to publish promising early clinical results in treating Ebola

EJ Lane SINGAPORE–Fujifilm's Toyama Chemical is readying a study for a scientific journal stating that its Avigan (favipiravir) influenza drug has shown promise in treating ...

Adaptimmune’s novel cancer treatment posts promising early results

Damian Garde Adaptimmune's pioneering approach to cancer immunotherapy has charted some impressive results in a small study. And while the biotech is quick to point out that it's ...

UPDATED: Ex-champ Vertex dumps hep C, but shares spike on positive CF results

John Carroll With Gilead's Sovaldi elbowing Vertex's Incivek aside, Vertex is calling it quits on a once-ambitious R&D effort to keep a niche for itself in hepatitis C. ...

GSK touts Anoro results as it preps for generic attacks on $8B-seller Advair

Carly Helfand With aging top dog Advair losing ground to generic and branded competitors alike, GlaxoSmithKline is grooming a lineup of respiratory up-and-comers to step in with their ...

Astellas, Medivation’s cancer drug Xtandi scores new upbeat PhIII results

Emily Mullin Medivation and Astellas Pharma unveiled final results on primary and secondary efficacy endpoints from their Phase III PREVAIL trial of Xtandi (enzalutamide), showing that ...

Sanofi and Regeneron Report Positive Results with Sarilumab

mia.burns Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial Sarilumab, Given Subcutaneously Every Other ...

Merck’s ‘breakthrough’ hep C combo plays catch-up with promising PhII results

John Carroll Merck may be playing catch-up in the race to develop the first all-oral combo treatment for hepatitis C, but it made a good case over the weekend that it has a real contender ...

InterMune Reports Third Quarter 2013 Financial Results And Business Highlights

barbara.lempert — Reports 8th Consecutive Quarter of Esbriet Revenue Growth — BRISBANE, Calif., Oct. 30, 2013 /PRNewswire/ — InterMune, Inc. (NASDAQ: ITMN) today ...

Interim analysis of triple-blind, randomized iMRI trial proves better results for glioma patients

barbara.lempert Interim analysis of triple-blind, randomized iMRI trial proves better results for glioma patients Fudan University neurosurgeons receive journal award at CNS for high-ranking ...

Medivir Shares Results from Simeprevir

mia.burns Medivir announces data from two phase III studies with Simeprevir in hepatitis C subpopulations – HCV/HIV co-infected and genotype 4 infected patients Stockholm, Sweden ...

Alnylam reports positive results for RNAi therapy

John Carroll Cambridge, MA-based Alnylam Pharmaceuticals says it garnered positive interim data from a Phase I study of ALN-TTRsc, an RNAi therapy targeting the transthyretin gene for ...
Page 1 of 712345...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS